GOLD study: An international Phase III study of TKI258/Dovitinib versus Sorafenib in patients with metastatic renal cell cancer (mRCC) as third line therapy

Titel:: GOLD study: An international Phase III study of TKI258/Dovitinib versus Sorafenib in patients with metastatic renal cell cancer (mRCC) as third line therapy
Dokumenttyp:: Meeting Abstract
Autor(en):: Grunwald, V; Kube, U; Eichelberg, C; Zürn, C; Gschwend, J
Zeitschriftentitel:: Onkologie
Jahr:: 2012
Band / Volume:: 35 6
Seitenangaben Beitrag:: 202-203
Sprache:: eng
Print-ISSN:: 0378-584X
TUM Einrichtung:: Urologische Klinik und Poliklinik
BibTeX

Vorkommen: